Induction of miR-29a by saturated fatty acids impairs insulin signaling and glucose uptake through translational repression of IRS-1 in myocytes  by Yang, Won-Mo et al.
FEBS Letters 588 (2014) 2170–2176journal homepage: www.FEBSLetters .orgInduction of miR-29a by saturated fatty acids impairs insulin signaling
and glucose uptake through translational repression of IRS-1 in
myocyteshttp://dx.doi.org/10.1016/j.febslet.2014.05.011
0014-5793/ 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
⇑ Corresponding author at: Department of Biochemistry, Dongguk University
College of Medicine, 87 Dongdae-ro, Gyeongju 780-714, Republic of Korea. Fax: +82
54 770 2447.
E-mail address: wanlee@dongguk.ac.kr (W. Lee).Won-Mo Yang a, Hyo-Jin Jeong a, Seung-Yoon Park a, Wan Lee a,b,⇑
aDepartment of Biochemistry, Dongguk University College of Medicine, Gyeongju 780-714, Republic of Korea
b Endocrine Channelopathy, Channelopathy Research Center, Dongguk University College of Medicine, Goyang 410-773, Republic of Korea
a r t i c l e i n f o a b s t r a c tArticle history:
Received 27 January 2014
Revised 11 April 2014
Accepted 2 May 2014
Available online 17 May 2014
Edited by Laszlo Nagy
Keywords:
MicroRNA
miR-29a
Palmitate
Insulin resistance
IRS-1
Saturated fatty acidMicroRNAs have been shown to play an important role in insulin signaling but their biological func-
tion in insulin resistance induced by saturated fatty acids (SFA) remains largely unknown. Here, we
report that SFA palmitate and high fat diet (HFD) signiﬁcantly increase expression of miR-29a in
myocytes. miR-29a targets IRS-1 3’UTR directly and represses IRS-1 expression at the translational
level. Furthermore, the ectopic expression of miR-29a impairs insulin signaling and glucose uptake
in myocytes through a substantial decrease in IRS-1. These ﬁndings suggest that the up-regulation of
miR-29a by SFA is causally related to the development of insulin resistance in myocytes.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction the insulin receptor to the down-stream enzymes, such as PI3K,Obesity is an increasing health problem, and appears to be tied
intimately to numerous metabolic diseases [1]. Excess lipid accu-
mulation in non-adipose tissues causes dysregulation of the cellu-
lar metabolism and apoptosis, which is known as lipotoxicity [1].
In particular, the accumulation of excess saturated fatty acids
(SFA) in skeletal muscle has been linked to the pathogenesis of
insulin resistance [2,3]. Insulin resistance is deﬁned as an inade-
quate response by insulin-sensitive tissues to ordinary levels of
insulin, and is one of the major characteristics of type 2 diabetes
mellitus (T2DM) and metabolic syndrome [2,3]. Although the
mechanism underlying SFA-induced insulin resistance in skeletal
muscle is unclear, several mechanisms have been suggested to
explain the impaired insulin signaling resulting from the dysregu-
lation of IRS-1 modiﬁcation and expression [1–4].
IRS-1 serves as the key molecule in mediating the metabolic and
mitogenic effects of insulin in peripheral tissues, such as skeletal
muscle, liver and adipose tissue, by transmitting the signals fromPDK-1, and Akt [5]. Excess SFA, particularly palmitate, increases
the intermediate lipid metabolites including ceramide and diacyl-
glycerol (DAG), which leads to the serine phosphorylation of IRS-1
via protein kinase C theta (PKC h), JNK and IKK [1,4]. Consequently,
the serine phosphorylation of IRS-1 causes the interruption of
downstream insulin signaling by inactivating IRS-1 and the degra-
dation of IRS-1 by ubiquitination [4,6,7]. Although inappropriate
post-translational modiﬁcation of IRS-1 by SFA has a major detri-
mental effect on the development of insulin resistance, a number
of studies have suggested that the down-regulation of IRS-1 in
skeletal muscle is also involved in the pathogenesis of insulin resis-
tance and T2DM [8]. The level of IRS-1 expression was reported to
be lower in skeletal muscle of obese-type T2DM animals, such as
ob/ob mice [9,10] and obese Zucker rats [11]. Furthermore, a
decrease in IRS-1 has been reported in skeletal muscle of T2DM
patients [12–15], indicating that the down-regulation of IRS-1 in
skeletal muscle is associated with insulin resistance and T2DM.
Nevertheless, the mechanism for how excess SFA down-regulates
IRS-1 in skeletal muscle at the post-transcriptional level except
for the serine phosphorylation of IRS-1 is largely unknown.
MicroRNAs (miRNAs) are highly conserved endogenous small
non-coding RNAs that regulate protein expression at the transla-
tional level by base-pairing with the 30 untranslated regions
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either the degradation of target mRNA or the suppression of trans-
lation, thereby regulating a range of gene functions in both normal
and pathological states [16,17]. In 2005, Mersey et al. [18] provided
the ﬁrst evidence that miRNA is involved in complex metabolic
processes, such as amino acid catabolism, in mammalian cells.
After the ﬁrst discovery that miRNAs are involved in metabolic reg-
ulation, there is growing evidence that a large number of miRNAs
is associated with the pathogenesis of insulin resistance and T2DM
[19,20]. Subsequent studies have indicated the important roles of
miRNAs in the regulation of insulin sensitivity in skeletal muscle
[20–22]. Recently, we have found that insulin resistance induced
by high fat diet (HFD) increased the expression of certain miRNAs,
such as miR-96, miR-126, and miR-29a, in skeletal muscle and
liver, and showed that miR-96 and miR-126 impaired insulin sig-
naling and glucose metabolism by reducing IRS-1 expression in
hepatocytes [20,23]. Although the miR-29 family is involved in a
range of biological processes, such as cellular metabolism and cell
proliferation [24,25], it is unclear if and how miR-29a is linked to
the regulation of insulin sensitivity in skeletal muscle.
Here, we reports that miR-29a is up-regulated by SFA palmitate,
and that it targets IRS-1 30UTR directly.miR-29a is also up-regulated
considerably in skeletal muscle and liver of diet-induced obese
(DIO) mice. The ectopic expression of miR-29a was found to cause
a substantial decrease in IRS-1 expression, leading to impaired insu-
lin signaling and glucose uptake in myocytes. Together, these ﬁnd-
ings suggest a novel mechanism where miR-29a is causally related
to the development of SFA-induced insulin resistance.
2. Materials and methods
2.1. Cell culture and palmitate treatment
L6 GLUT4myc (provided by Dr. Amira Klip, the Hospital for Sick
Children, Toronto, Ontario, Canada), originating from rat skeletal
muscle, were cultured in MEM alpha with 10% FBS and 1% penicil-
lin–streptomycin [26]. For the palmitate treatment, the cells were
incubated for 18 h with BSA or BSA conjugated-palmitate (0.1–
0.5 mM). After treatment, the cells were serum-starved for 4 h
and stimulated with insulin (100 nM) for 30 min.
2.2. Animal and HFD-induced insulin resistance
All animal procedures were performed in accordance with the
rules of Animal Use and Care Committee at Dongguk University.
C57BL/6 mice were purchased from Central Lab. Animal, Inc (Seoul,
Korea). Mice were kept in a temperature-controlled facility with a
12:12 h light–dark cycles and given access to food and water
ad libitum. At 6 weeks of age, mice were fed either control diet
(11% calories from fat) or HFD (60% calories from fat; Test Diet
Richmond, IN) for 15 weeks. The body weight was measured every
week. At the end of experiment, mice were fasted overnight and
subjected to biochemical analysis.
2.3. Transfection of miRNA mimics and plasmids
L6 GLUT4myc myocytes were grown up to approximately 70%
conﬂuence on the day of transfection. The cells were transfected
with scrambled control (scRNA), miRNA mimics, anti-miRNA mim-
ics, and/or plasmids using Lipofectamine 2000 (Invitrogen).
2.4. RNA preparation and quantitative real-time RT-PCR (qRT-PCR)
The total cellular RNA was isolated using QIAzol (Qiagen). For
RT-PCR, cDNA was synthesized using M-MLV reverse transcriptase(Promega) and ampliﬁed with oligo dT (Bionics, Seoul, Korea) as
described elsewhere [23]. To measure the miRNA expression level
using qRT-PCR, miRNA isolated using a miRNeasy Mini Kit (Qia-
gen). The cDNA was synthesized using miScript reverse transcrip-
tion Kit (Qiagen) and then was performed qRT-PCR using miScript
SYBR Green PCR Kit (Qiagen) according to the manufacturer’s
instructions using the Light-Cycler480 system (Roche-Applied
Science). U6 snRNAs was used as the internal control.
2.5. Luciferase reporter gene assay
The reporter gene constructs were generated by cloning IRS-1
30UTR containing either the miR-29 family binding sites (IRS-1
3Uwt) or the mutated miR-29 family binding sites (IRS-1 3Umut-
1, IRS-1 3Umut-2 or IRS1 3Umut-3) into the pmirGLO Dual-lucifer-
ase miRNA target expression plasmid (Promega) as illustrated in
Fig. 2A and B. The luciferase assays were performed using a Dual
luciferase reporter system (Promega) according to the manufac-
turer’s instructions. Brieﬂy, A miR-29a mimic or scRNA (100 nM)
was co-transfected with pmirGLO plasmids containing empty,
wild-type (IRS-1 3Uwt) or mutants (IRS-1 3Umut-1, IRS-1 3Umut-
2 and IRS-1 3Umut-3) to L6 GLUT4myc myocytes. After 24 h, the
cells were lysed using a passive lysis buffer, and the Fireﬂy and
Renilla luciferase activities were measured on a Sirius L (Titertek-
Berthold, Germany). The relative luciferase activity was calculated
by normalizing the ratio of Fireﬂy/Renilla luciferase to that of the
scRNA-transfected cells.
2.6. Glucose uptake analysis
The L6 GLUT4myc cells were transfected with miR-29a, -29b
mimics or scRNA in a Lab-Tek chamber slide (Thermo). After
48 h, the cells were serum starved for 4 h and incubated for
40 min in a glucose-free medium without FBS. The cells were stim-
ulated with insulin (100 nM) for 20 min, challenged with GB2-Cy3
(5 lM) for 20 min, and then analyzed by ﬂuorocytometry
(550570 nm) as described [27].
2.7. Gel electrophoresis and immunoblotting
The cell lysates in Laemmli solution were subjected to SDS–
PAGE and immunoblot analysis, as described [23]. The antibody
against IRS-1 was obtained from Upstate (Lake Placid, NY) and
the antibody against phospho-IRS-1 was supplied by Invitrogen.
All other antibodies were purchased from Cell Signaling (Beverly,
MA). The proteins were visualized using an enhanced chemilumi-
nescent substrate kit (NEN Life Science). The immunoblot intensi-
ties were quantiﬁed by densitometry using an analytical scanning
system (Alpha Imager HP, Alpha Innotech).
2.8. Statistical analysis
The values are expressed as the mean ± SEM from at least three
independent experiments. Where applicable, the signiﬁcance of
the differences was analyzed using a Student’s t test for the
unpaired data.
3. Results
3.1. Up-regulation of miR-29a expression by SFA and HFD
To examine the effect of SFA on insulin signaling in myocytes,
L6 GLUT4myc myocytes were treated with palmitate, which is
among the most common SFA distributed in skeletal muscle [28].
After palmitate treatment (0.1–0.5 mM for 18 h), the level of
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Fig. 1. Up-regulation of miR-29a by SFA and HFD. (A) L6 GLUT4myc myocytes were treated with palmitate (0.1–0.5 mM) for 18 h. The expression of insulin signaling
intermediates (IRS-1, and Akt2) was analyzed by immunoblot (upper panel). The immunoblot intensities of IRS-1/b-Actin were quantiﬁed by densitometry (lower panel) and
are expressed as the relative ratio where the intensity of control (open column) was set to one. (B) The mRNA level of IRS-1 were quantiﬁed by qRT-PCR from control and
palmitate-treated (0.1–0.5 mM for 18 h) myocytes. (C) Myocytes were preincubated with or without palmitate (0.5 mM) for 18 h. The cells were serum-starved for 4 h and
then, incubated in the presence or absence of insulin (100 nM) for 30 min. The expression (IRS-1 and Akt2) and phosphorylation (pIRS-1 and pAkt2) of insulin signaling
intermediates were analyzed by immunoblot. The immunoblot intensities were quantiﬁed by densitometry with b-actin as an internal control, and are expressed as the
relative ratio, where the intensity of the control (open column) was set to one. (D) The expression of miR-29a were quantiﬁed by qRT-PCR from control and palmitate-treated
(0.1–0.5 mM for 18 h) myocytes. The values are expressed as the relative ratio where the intensity of control (open column) was set to one. (E) The expression of IRS-1 was
analyzed by immunoblot in skeletal muscle and liver from control and HFD-fed mice. (F) The expression of miR-29a was quantiﬁed by qRT-PCR from control and HFD-fed
mice. The values are expressed as the relative ratio, where the intensity of the normal control was set to one. Values are means ± SEM from at least three independent
experiments; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
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manner (Fig. 1A) without changing its mRNA level (Fig. 1B) com-
pared with control, whereas the expression of Akt2 or b-actin
was unaffected (Fig. 1A). Furthermore, palmitate treatment
(0.5 mM for 18 h) reduced signiﬁcantly the insulin-stimulated
phosphorylation of IRS-1 and its downstream substrate, Akt2, in
myocytes (Fig. 1C). These results clearly show that a SFA palmitate
impairs insulin signaling in myocytes through a reduction in IRS-1
expression.
As palmitate reduced IRS-1 expression in myocytes, we next
analyzed the expression of several miRNAs, such as miR-96, miR-
126, and miR-29a, which presumably target a segment of IRS-
130UTR. According to qRT-PCR, the expression of miR-29a was
induced signiﬁcantly in palmitate-treated myocytes in a dose-
dependent manner (Fig. 1D), suggesting that miR-29a may be
involved in the reduced expression of IRS-1 and insulin resistance
by SFA. It has been well known that diet-induced obesity (DIO)
causes insulin resistance, and type2 diabetes in skeletal muscle
and liver [1]. Therefore, miR-29a levels in insulin responsive
tissues, such as skeletal muscle and liver, in DIO mice were also
analyzed. In our study, HFD (60% kcal from fat for 15 weeks) in
mice resulted in hyperglycemia, impaired oral glucose tolerance,
and insulin resistance (Suppl 1). As expected, the level of IRS-1
expression was reduced drastically in both skeletal muscle andliver of DIO mice (Fig. 1E). Furthermore, the expression of miR-
29a was up-regulated signiﬁcantly in skeletal muscle and liver of
DIO mice (Fig. 1F). These results clearly show that SFA or HFD
up-regulates miR-29a expression in myocytes with a concomitant
decrease in IRS-1 protein level, insinuating the implication of miR-
29a on insulin resistance by SFA.
3.2. Conﬁrmation of miR-29a targeting in IRS-1 3’UTR
In silico target analysis, such as TargetScan (http://www.target-
scan.org) and PicTar (http://www.pictar.org), indicated that the
30UTR of IRS-1 gene contains two predicted binding sites for miR-
29a (Fig. 2A). A pmirGLO-based 30UTR reporter vector consisting
of a luciferase cDNA followed by the 828 nt 30UTR of the IRS-1 gene,
which contains two potential miR-29a binding sites (wild-type;
IRS-1 3Uwt), was constructed to determine if miR-29a can interact
with the predicted binding sites in the 30UTR of IRS-1 gene and sub-
sequently inhibit IRS-1 expression (Fig. 2B). The plasmids, which
contained single mutated (IRS-1 3Umut-1 and IRS-1 3Umut-2) or
double mutated (IRS-1 3Umut-3) miR-29a binding sites in the
30UTR of the IRS-1 gene (Fig. 2A and B), were also analyzed. The
plasmid DNA of each reporter (IRS-1 3Uwt, IRS-1 3Umut-1, IRS-1
3Umut-2 or IRS-1 3Umut-3) was cotransfected with miR-29a
mimics or scRNA into L6 GLUT4myc myocytes. According to the
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and IRS-1 3Umut-2 were reduced signiﬁcantly by miR-29a mimic,
whereas the luciferase activities of IRS-1 3Umut-1 and IRS-1
3Umut-3 were not affected. This results clearly indicated that the
ﬁrst binding site (Site #1) for miR-29 family on IRS-1 30UTR is nec-
essary for IRS-1 repression by miR-29a. In addition, miR-29b and -
29c mimics did not reduce signiﬁcantly the luciferase activities of
IRS-1 3Uwt, IRS-1 3Umut-1, IRS-1 3Umut-2 and IRS-1 3Umut-3 in
this assay (data not shown). Therefore, miR-29a targets IRS-1
30UTR directly and represses IRS-1 expression at the translational
level.
3.3. Repression of IRS-1 by ectopic expression of miR-29a
As IRS-1 30UTR is a direct target of miR-29a, the ectopic expres-
sion of miR-29a should reduce the IRS-1 protein without altering
mRNA level in myocytes. To examine this further, L6 GLUT4myc
myocytes were transfected with miR-29a, -29b mimics, or scRNA
control, and the expression of IRS-1 was analyzed. As shown in
Fig. 3A and Suppl 2, the ectopic expression of miR-29a resulted
in a signiﬁcant reduction of IRS-1 protein without an apparent
change in IRS-1 mRNA compared to scRNA control. On the otherhand, any of miR-29 mimics did not affect the protein and mRNA
levels of Akt2 and GSK3b in myocytes. To conﬁrm IRS-1 regulation
by miR-29a, the antisense miR-29a mimic (AntimiR-29a) was over-
expressed in the presence or absence of miR-29a in myocytes
(Fig. 3B). AntimiR-29a slightly increased IRS-1 expression as com-
pared to scRNA control and completely rescued the miR-29a-
induced IRS-1 repression in myocytes. These results indicate that
miR-29a regulates the expression of IRS-1 in myocytes.
3.4. Impaired insulin signaling and glucose uptake by ectopic
expression of miR-29a
Since miR-29a reduces IRS-1 expression by directly targeting
the 30UTR of IRS-1, the up-regulation of miR-29a might impair
insulin signaling and insulin-stimulated glucose uptake in myo-
cytes. Therefore, we analyzed the insulin-stimulated phosphoryla-
tion of insulin signaling intermediates and glucose uptake in the
presence or absence of the ectopic expression of miR-29a in myo-
cytes (Fig. 4). The level of IRS-1 expression was reduced signiﬁ-
cantly (by 60%) by ectopic expression of miR-29a mimic,
whereas the expression of Akt2 and GSK3bwas unaffected, as com-
pared to control (Fig. 4A). As expected, the ectopic expression of
miR-29a reduced signiﬁcantly the insulin-stimulated phosphoryla-
tion of IRS-1 and its downstream kinases, Akt2 and GSK3b, in myo-
cytes (Fig. 4A–C). This was attributed mainly to a decrease in IRS-1
expression. In addition, we examined how miR-29a affects the
insulin-stimulated glucose uptake in the presence or absence of
insulin (Fig. 4D). In the control, insulin increased glucose uptake
drastically, as assessed with the GB2 intensity, whereas insulin-
stimulated glucose uptake was barely observed in miR-29a-over-
expressed cells. The myocytes overexpressed with miR-29b exhib-
ited glucose uptake responding to insulin as similar to control.
Taken together, the ectopic expression of miR-29a impairs insulin
signaling and insulin-stimulated glucose uptake in myocytes
through the translational repression of IRS-1.
4. Discussion
SFA palmitate decreased the expression of IRS-1, leading to
impaired insulin signaling and glucose uptake in myocytes. As
the drastic decrease in IRS-1 was robust at the protein level but
barely observable at the mRNA level (Fig. 1), it was suspected that
the post-transcriptional repression of IRS-1 expression might occur
via a miRNAs-mediated mechanism. The treatment of SFA
increased the expression of miR-29a (Fig. 1), and miR-29a
decreased IRS-1 expression directly through translational repres-
sion (Figs. 2 and 3), resulting in insulin resistance in myocytes
(Fig. 4). Furthermore, miR-29a was up-regulated in skeletal muscle
of DIO mice (Fig. 1) and obese-type T2DM animals [29,30]. There-
fore, miR-29a has a novel function in insulin signaling and the cel-
lular metabolism, and the induction of miR-29a by SFA is involved
in the pathogenesis of insulin resistance in skeletal muscle.
The miR-29 family comprises of three mature forms, miR-29a, -
29b and -29c, and their seed sequences are highly conserved in
most species [24]. Thus far, approximately 50 target genes of the
miR-29 family members have been validated experimentally from
thousands of predicted target genes [24]. Based on the functional
relevance and target validation studies by ectopic expression, the
miR-29 family is involved in a variety of biological processes, such
as cellular metabolism, cell proliferation, differentiation, hemato-
logical function and immune modulation [24,25]. On the other
hand, the roles and functional signiﬁcance of the miR-29 family
in insulin resistance and diabetes are largely unknown. This study
found that the cellular treatment of SFA up-regulated the expres-
sion of miR-29a in myocytes. Moreover, miR-29a was increased
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that an increase in miR-29a is associated with the pathogenesis
of insulin resistance and diabetes. Although miR-29b and miR-
29c were also increased approximately 1.5-fold by SFA (data not
shown), similar to miR-29a, the absolute levels of miR-29b and
miR-29c expression in L6 GLUT4myc myocytes and skeletal muscle
of DIO mice were negligible compared to miR-29a (Suppl 3). miR-
29a appears to be expressed constitutively and ubiquitously during
the cell cycle, whereas miR-29b is expressed at low-levels, except
in mitosis stage, and decays rapidly; miR-29c is even less detect-
able [31]. A distinct regulation mechanism of miR-29 family might
exist in myocytes, which remains to be explored further. For this
reason, this study focused on the implications of miR-29a in insulin
resistance induced by SFA.
Recently, He et al. [29] reported that the miR-29 family is up-
regulated in insulin-responsive tissues, such as skeletal muscle,
liver, and adipose tissues of obese-type diabetic Goto-Kakizaki rats.
More recently, Karolina et al. [30] found that the levels of miR-29a
are increased in skeletal muscle, liver, and adipose tissues, as well
as in the blood from T2DM rat model induced by HFD and low
doses of STZ. In this study, miR-29a was up-regulated in the myo-
cytes treated with SFA and skeletal muscle of DIO mice. Corre-
sponding to previous results, the up-regulation of miR-29a in the
insulin responsive tissues appears to be a characteristic feature
of obese-type T2DM. The mechanism through which excess SFA
up-regulates the expression of miR-29a is unclear. Nevertheless,
multiple reports have revealed several transcriptional factors, such
as NF-jB, c-Myc, CEBPA, and p53, which bind to speciﬁc sites on
the miR-29a gene promoter regions [24,32]. Among these, CEBPA
is a well-known adipogenic gene that responds to high energy
nutrients [33]. Recently, CEBPA was found to activate the miR-
29a/b1 cluster directly in acute myeloid leukemia [34]. In addition,
p53, a well-known tumor suppressor, was reported to induce the
transcriptional activation of miR-29 in response to oxidative stress
[35] and DNA damage [36]. Moreover, SFA and obesity is involved
in ROS generation and cellular oxidative stress [1,4], and that the
levels of CEBPA and p53 expression are up-regulated in DIO mice
[33,37]. Although further study is warranted, the up-regulation of
miR-29a might be triggered by SFA and obesity through the tran-
scriptional activation of p53 and/or CEBPA.
We for the ﬁrst demonstrated that the overexpression of miR-
29a represses IRS-1 expression via the direct targeting of IRS-1
30UTR (Figs. 2 and 3). Although the seed region is identical, miR-
29b neither suppressed IRS-1 expression nor abolished insulin-
stimulated glucose uptake (Fig. 4). It has been known that the seed
pairing is important in post-transcriptional repression by miRNAs.
However, recent studies in the target recognition and silencing
efﬁcacy of miRNAs revealed alternative modes of miRNAs’ action
beyond seed pairing, such as 30 compensatory sites, bulged sites,
30UTR duplex structure, etc. [38–40]. Since the nucleotide sequence
in 30 compensatory sites and bulged sites against IRS-1 30UTR is dif-
ferent between miR-29a and -29b (Fig. 2A), they may exhibit a dis-
tinct duplex structures and target-off machinery, resulting in
highly variable efﬁcacy of miRNA-mediated target repression. Fur-
ther studies are warranted. Nevertheless, the discovery that the
induction of miR-29a inhibits insulin signaling through IRS-1
repression provides novel insights into the molecular basis under-
lying SFA-induced pathogenesis of insulin resistance. In addition,
Akt2, Akt3, regulatory domain of PI3Kinase, and GSK3b, which play
important roles in insulin signaling and glucose uptake in myo-
cytes, were suggested to be potential candidate genes of miR-29a
by in silico analysis. However, there were no meaningful changes
in the downstreammolecules of IRS-1. Therefore, it is believed that
the inﬂuence of miR-29a on target expression in insulin signaling
might differ according to the species, cell type, UTR contexts, and
duplex structure.In conclusion, we have demonstrated that miR-29a induced by
SFA or HFD causes insulin resistance in myocytes through transla-
tional repression of IRS-1. SFA and obesity generate the signals
related to oxidative stress, inﬂammation, and ER stress, and acti-
vates several kinases and transcriptional factors, such as p53 and
CEBPA. These changes might activate the production and process-
ing of miR-29a, leading to IRS-1 post-transcriptional repression
and subsequent insulin resistance. Further research into the meta-
bolic signals and transcriptional factors involved in miRNA-medi-
ated insulin resistance are currently underway.
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